Aegros Secures Final Funding for Completion of its 125,000 Litre Haemafrac® Facility
Aegros Secures Final Funding for Completion of its 125,000 Litre Haemafrac® Facility Yolanda Redrup July 3, 2025 An Australian biotech start-up hoping to emulate the success of blood plasma giant CSL has secured a $37 million lifeline eight months after it was forced to suspend operations unable to repay mounting debts. Staff at Aegros were […]
Aegros Announces Share Purchase Plan Capital Raising Precusor to IPO
From the FoundersAs of next month it will be 38 years since we started this journey, in May 1985. While that may appear to be an exceptionally long time, it talks to the tenacity, complexity and tortuous path one has to travel to bring a new technology to commercial reality. Today we can say we […]
Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune – TGA Application to follow
WATCH NOW – Aegros Founders and Chief Medical Officer discuss the interim CHAT results. Date: 01 December 2023 Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial. Top-line interim results indicate that Aegros’ COVID-19 hyperimmune […]
Australia’s leading blood fractionator announces a trio of strategic advisor appointments as it lays the groundwork for an IPO
Sydney, 23 November: AEGROS today cemented itself as the leading new technology blood fractionator in Australia by announcing a number of key advisory appointments that will help guide the company towards an Initial Public Offering during 2024. Initial appointees to the Strategic Advisory Committee bring the following expertise and profile to the company: The move […]
Aegros Board on The Voice Referendum
The Aegros Board is proud to issue the following statement in support of The Uluru Statement and Voice to Parliament referendum.
Shareholder Announcement: Ernst & Young Appointed as Auditors
Aegros is pleased to announce the appointment of Ernest & Young (EY) as our new Auditors. The Board of Aegros has resolved to appoint EY as the Company’s Auditors replacing Hall Chadwick, effective for the 2022-23 Audit. The Board has taken this action as part of the Company’s preparation for an expected IPO in the […]
Aegros presents Industry Scale-up Case Studies Video
Aegros was proud to sponsor a session on Industry case studies: Commercial Scale-up and we share with you the words of industry experts and, where approval has been given, the content of their presentations as well. The session was held as a break-out during the Advanced Biomanufacturing Training Workshop at the Australian Institute of Biomanufacturing […]
Historic Joint Venture to Build 1m Litre HaemaFrac® Facility in Singapore & Cambodia
Media Statement – Australia’s Leading Technology fractionator signs US$400m historic joint venture agreement to build 1m litre HaemaFrac® facility in Singapore & Cambodia Sydney, August 7: AEGROS today announced a ground-breaking agreement to build a fully funded US$400m 1,000,000 litre HaemaFrac® plasma fractionation facility in Singapore, with a sterile fill and finish facility in Cambodia, […]
Thanks to Staff With A Mid-Year Feast
Aegros celebrated the end of financial year and the successful completion of several important milestones with a fantastic lunch that provided the Aegros team with the flavours of South India on a winter’s day. Caption: Aegros Co-founders Professor Hari Nair and Mr John Manusu address the Aegros team to express their thanks for a successful […]
Promoting and Protecting Future Science and Scientists
Aegros recently had the pleasure of hosting two work experience students from the German International School Sydney (GISS), to give them an insight into what Science, Technology, Engineering and Mathematics (STEM) looks like in a commercial setting. Aegros’ Research & Development team was pleased to host the students, Niamh D’Mello and Seungheon (Daniel) Choi, who were […]
